Skip to main content
Premium Trial:

Request an Annual Quote

Human Longevity Raises $30M From Emerging Technology Partners, Healthcare Investors

NEW YORK – Human Longevity said on Wednesday that it has closed a $30 million financing round from a number of investors.

The round included existing investor Emerging Technology Partners as well as new undisclosed healthcare investors.

The San Diego-based company plans to use the proceeds from the financing to enhance its Health Nucleus intelligence platform, which combines brain and body MRI imaging, whole-genome sequencing, and other lab tests such as cardiac CAT scans and metabolic tests with machine learning and artificial intelligence to create "a comprehensive standard for measuring your health and performance."

The platform provides risk analyses for cardiac, cancer, metabolic, and cognitive health issues.   

Human Longevity's latest funding round follows a $220 million Series B funding that company completed in 2016.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.